Comparative Pharmacology
Head-to-head clinical analysis: CAPOTEN versus MAVIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOTEN versus MAVIK.
CAPOTEN vs MAVIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, and increased plasma renin activity.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and reduced cardiac workload.
50 mg orally three times daily initially; maintenance 50-100 mg three times daily; maximum 450 mg/day.
Oral, 1-4 mg once daily for hypertension; 2-4 mg once daily for heart failure.
None Documented
None Documented
Terminal elimination half-life is approximately 1.9 hours in healthy subjects, but prolonged in heart failure (up to 3-4 hours) and renal impairment (up to 5-10 hours).
Trandolaprilat: terminal half-life ~24 hours (range 15–35 hours) for once-daily dosing; effective half-life ~6–10 hours at steady state.
Primarily renal (approximately 60-75% as unchanged drug and metabolites) and biliary/fecal (approximately 20%).
Renal: trandolapril ~33% (as trandolaprilat and metabolites), trandolaprilat ~33% (as unchanged and metabolites); biliary/fecal: ~66% of total radioactivity.
Category C
Category C
ACE Inhibitor
ACE Inhibitor